Twist Bioscience is overbought with RSI at 72 and already 28% above analyst price targets, carrying 31% short interest and burning cash at 14% of revenue, while concentration in synthetic DNA products and a sole-source supplier create compounding risks.
Thesis pillars
- Severe Negative Asymmetry→Stable
- Synthetic Dna Supplier Concentration→Stable
- Cash Burn 31 Percent Short→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Nov 17, 2025· older than 90 days
Twist Bioscience Corporation (TWST) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $112.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation.
Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, selling synthetic genes, NGS tools, and biopharma services to more than 3,800 customers in healthcare, chemicals/materials, academic research, and food/agriculture. The company reported $376.6... Read more
Sell if holding. Engine safety override at $112.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 5/8 gates (no SEC red flags, news boost analyst 0.60, earnings proximity 75d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and clean insider activity. Suitability: speculative.
About Twist Bioscience Corporation
About Twist Bioscience Corporation
Twist Bioscience generated $376.6 million in revenue in fiscal year 2025, split across healthcare ($215.1 million), chemicals/materials ($93.2 million), academic research ($65.9 million), and food/agriculture ($2.4 million). The company served more than 3,800 customers and employs 412 people in manufacturing and operations and 91 in research and development as of September 30, 2025. Substantially all revenue to date comes from synthetic DNA products.
Twist generates revenue through two primary product lines — synthetic biology tools and NGS tools — plus biopharma services for antibody discovery and optimization. Synthetic biology products include synthetic genes, gene fragments, oligo pools, and IgG proteins; NGS tools include library preparation kits, human exome kits, fixed and custom panels, and Alliance panels. The company sells through a direct salesforce and e-commerce platform, employing 278 people in sales, marketing, and customer support as of September 30, 2025. Biopharma partnerships generate revenue through licensing fees, fee-for-service arrangements, and success-based milestones; as of September 30, 2025, Twist had signed 442 revenue-generating partnerships with clients including Bayer, Boehringer Ingelheim, and Takeda Pharmaceutical, with 82 programs including milestones and/or royalties. In October 2024, Twist agreed with XOMA Royalty to receive $15 million cash in exchange for 50% of future milestone and royalty payments from existing collaborations. In synthetic biology, the company competes with GenScript Biotech Corporation and Integrated DNA Technologies (owned by Danaher Corporation); in NGS tools, with Thermo Fisher Scientific, Illumina, and Roche Holding AG.
Show full overview
The 10-K discloses that Twist depends on one single-source supplier for a critical component of its DNA synthesis process. Although Twist maintains a reserve of supplies and acknowledges that alternative suppliers exist, the loss of this supplier or failure to supply the necessary component on time could cause delays in future capacity and may impact operations — a notable risk given that the gene synthesis business requires manufacturing to run 24 hours a day, seven days a week, 365 days per year with no seasonal slack. The filing does not name the supplier or the specific component.
See also: Healthcare · Biotechnology
From Twist Bioscience Corporation's most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated Nov 17, 2026Recent Developments — Twist Bioscience Corporation
Latest news
- NEWS ARK Investment Management Trims Position in Twist Bioscience — fiscal.ai Nov 17, 2026
- NEWS Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $130 — benzinga Nov 16, 2026 negative
- NEWS Wall Street Analysts Update Ratings and Price Targets for Twist Bioscience — fiscal.ai Nov 15, 2026 neutral
- NEWS Canaccord Genuity Cuts Twist Bioscience Price Target to $150 — fiscal.ai Nov 13, 2026 negative
- NEWS Baird Maintains Buy Rating on Twist Bioscience and Raises Price Target to $135 — fiscal.ai Nov 13, 2026 positive
Latest item Nov 17, 2026 · Generated 2026-11-18T12:02:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductsynthetic DNA products10-K Item 1A: 'Substantially all of our revenue generated to date is from our synthetic DNA products'
- HIGHSuppliersingle-source supplier10-K Item 1A: 'We depend on one single-source supplier for a critical component for our DNA synthesis process'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $112.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $104.16. Score 5.0/10, moderate confidence.
Analyst target: $112.16 (+0.1% upside). Prior stop was $104.16. Stop-loss: $104.16.
Concentration risk — Product: synthetic DNA products; Concentration risk — Supplier: single-source supplier; Target reached (0.1% upside).
Twist Bioscience Corporation trades at a P/E of N/A (forward -280.0). TrendMatrix value score: 3.0/10. Verdict: Sell.
19 analysts rate TWST, with a consensus score of 4.1/5. 12 analysts publish price targets averaging $129.
What does Twist Bioscience Corporation do?Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, selling synthetic genes, NGS...
Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, selling synthetic genes, NGS tools, and biopharma services to more than 3,800 customers in healthcare, chemicals/materials, academic research, and food/agriculture. The company reported $376.6 million in revenue in fiscal year 2025, generating fees through product sales and biopharma partnership milestones.